Collegium Pharmaceutical Inc., of Canton, Mass., reported net product revenues totaling $73.1 million for the second quarter vs. $3.6 million for the same period in 2017. Net product revenue was $18.1 million for tamper-resistant opioid Xtampza ER (oxycodone extended-release) and $55 million for the Nucynta (tapentadol) pain drug franchise.